PharmaceuticalsThe female Viagra, undone by a drug maker's dysfunction | The New York Times
Addyi, a pill developed by Sprout Pharmaceuticals to treat low sex drive in women, was approved last year by the Food and Drug Administration. Analysts predicted big sales, and in clinical trials, women reported a small but statistically significant increase in the amount of satisfying sexual experiences per month. Valeant Pharmaceuticals International then purchased Sprout for $1 billion. But weeks after the deal, Valeant came under fire for raising drug prices, its stock plummeted, and the company has dismissed the sales force behind Addyi. Valeant now says it will reintroduce Addyi this year.
The one drug pricing idea Hillary Clinton and PhRMA can agree on | STAT
Most of Hillary Clinton's ideas to reduce drug costs have been met with opposition from the pharmaceutical industry. But capping out-of-pocket costs for consumers is one proposal drug company trade group Pharmaceutical Research and Manufacturers of America supports, according to the organization's president and CEO, Stephen Ubl.
Safety, quality and clinical practiceBrazilian doctor crafts system hailed as 'way forward' for combating Zika | NPR
Poor infrastructure, unequal access to healthcare and the sheer size of Brazil make it hard for a mom with a microcephalic baby to travel from the countryside to see a specialist. So, pediatric cardiologist Dr. Sandra Mattos has developed a telemedicine system to treat babies remotely, from her laptop.
Highmark, UPMC play ground game on concussion testing | Pittsburgh Post-Gazette
Pittsburgh healthcare providers Highmark and UPMC have each introduced concussion screening tests for children as the rivals compete for market share.
575 dialysis patients may have been exposed to disease | MassLive.com
Baystate Medical Center, Springfield, Mass., has informed 575 kidney dialysis patients that the hospital failed to adhere to standard protocol and might have exposed them to pathogens.